SIRT5 has been shown to contribute to cisplatin resistance in ovarian cancer through modulation of the Nrf2/HO-1 pathway and to suppress tumor growth in gliomas by regulating mitochondrial metabolism [8]. Here, SIRT5 is linked to glioma.